Carl Zeiss revenue increases 12.1%
evenue of €758.8m in financial year 2010/2011, compared to €676.7m the previous year. This corresponds to an increase of 12.1 per cent at the close of its financial year ending 30 September 2011.
“Despite the adverse general economic situation we have been able to continue our growth course and even exceed our expectations,†says Dr Ludwin Monz, president and CEO of Carl Zeiss Meditec AG.
“Although we continued to invest in new products, and to establish and expand our sales and service structures, we have succeeded in increasing profitability. This is not least because we managed to further improve the manufacturing cost position,†said Dr Monz.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.